Tezepelumab-ekko side effects
- Generic Name: tezepelumab-ekko
- Brand name: Tezspire
- Dosage Form: injection, for subcutaneous use
- Medically reviewed by R Shah MD. Updated on March 20, 2022.
What is tezepelumab-ekko?
Tezepelumab-ekko side effects are unwanted reactions that may be experienced while using this drug
Tezepelumab-ekko is a human monoclonal antibody immunoglobulin G2 (IgG2) generated in Chinese hamster ovary (CHO) cells using recombinant DNA technology. It is a thymic stromal lymphopoietin (TSLP) blocker. The molecular weight of tezepelumab-ekko is approximately 147 kDa.
Tezepelumab-ekko injection is a single-dose vial or single-dose pre-filled syringe of sterile, preservative-free, clear to opalescent, colorless to light yellow solution for subcutaneous injection.
Each single-dose vial or pre-filled syringe contains 1.91 mL of tezepelumab-ekko, 2.8 mg of glacial acetic acid, 48 mg of L-proline, 0.19 mg of polysorbate 80, sodium hydroxide, and water for injection. The pH of the water is 5.2.
Tezepelumab-ekko is a prescribed medicine that is used in conjunction with other asthma medications to treat severe asthma in patients who are 12 years old or older whose asthma isn’t controlled by their current asthma medication.
Tezepelumab-ekko is a great way to stop serious asthma attacks (exacerbations) and improve your breathing.
Tezepelumab-ekko is not intended to treat breathing issues that arise suddenly. Inform your doctor when your asthma doesn’t improve or becomes worse following the start of treatments with Tezepelumab-ekko .¶
It isn’t known whether this medication can be used safely and effectively for children younger than 12 years old. age.¶
Who should not receive Tezepelumab-ekko ?
Do not get this medication if:
- Are allergic to tezepelumab or any other ingredients. Look at the end of this page for a full listing of the ingredients.
Prior to receiving Tezepelumab-ekko
Before you get this medication, inform your healthcare provider of the medical conditions you suffer from for example if you
- Have you ever experienced an extremely severe allergic reaction (hypersensitivity).
- are suffering from an infection called a parasite (helminth) disease.
- Recently, or recently, they have received or are scheduled to receive any live vaccines attenuated to live. The Tezepelumab-ekko vaccine is recommended for those who have not received live vaccines attenuated to the point of inactivity.
- If you are pregnant, it is possible that you could be pregnant or planning to be expecting. It’s unclear whether Tezepelumab-ekko can affect your baby’s development.
- If you are nursing or planning to or plan to. It’s not clear whether Tezepelumab-ekko gets into your milk. Discuss with your healthcare professional the best method to feed your child if you are receiving Tezepelumab-ekko .
Mechanism of Action
Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, a human monoclonal antibody IgG2 that binds to human TSLP and blocks its interaction with the heterodimeric TSLP receptor with a dissociation constant of 15.8 pM. TSLP is a cytokine produced mostly by epithelial cells that has a role in the asthma inflammatory cascade.
Inflammation of the airways is a key factor in the development of asthma. Airway inflammation is caused by a variety of cell types (mast cells, eosinophils, neutrophils, macrophages, lymphocytes, and ILC2 cells), as well as mediators (histamine, eicosanoids, leukotrienes, and cytokines). Blocking TSLP with tezepelumab-ekko lowers inflammatory biomarkers and cytokines like blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13; however, the mechanism of tezepelumab-ekko action in asthma has yet to be determined.
What other drugs can impact Tezepelumab-ekko ?
Discuss with your doctor the medications you are taking such as prescription and over-the-counter supplements including vitamins, supplements, and herbal supplements. Do not alter or stop taking corticosteroid medications or other asthma medicine unless your doctor advises you to.
How do I get Tezepelumab-ekko ?
- Your doctor will offer your Tezepelumab-ekko in a hospital setting.
- Tezepelumab-ekko is injected into the skin (subcutaneously) one time every 4 weeks.
- If you do not make the appointment, you should inform your doctor when you can schedule your next appointment.
Tezepelumab-ekko side effects
For consumers
This medication may cause serious side effects, including:
- extremely allergic reactions. Consult your physician or seek emergency medical attention in the event that you exhibit any of the following signs of an allergic reaction:
- It is a rash
- Hives
- breathing issues
- Red, itchy swelling, or red eyes
The most frequent adverse effects are:
- Sore throat (pharyngitis)
- joint discomfort (arthralgia)
- Back in pain
This is not the only list of the possible adverse consequences. Consult your physician to seek medical advice on adverse effects. You can report symptoms to FDA at 1-800-FDA-1088.
For professionals
General
- The most frequently reported adverse reactions to include Pharyngitis as well as arthralgia and lower back discomfort
Respiratory
- The most common (1 10% to 10 10%) Pharyngitis (including streptococcal and bacterial infections) as well as viral)
Immunologic
- The most common (1 10% to 10 10%) Anti-drug antibodies
Musculoskeletal
- The most common (1 10% to 10 10%) Arthralgia, back pain
Local
- Common (1% to 10%): Injection site reactions (e.g., injection site erythema, injection site swelling, injection site pain)
How Supplied
The injections are a preservative-free, sterile clear to opalescent clear to light yellow, colorless solution that is available as a single-dose vial or single-dose vial with a 27 gauge fixed 1/2 inch needle, with needle covers. The cap for the needle and vial stopper is not made from natural latex rubber.
This is available in the following formats:
- Single-Dose vial: Carton has a dose of 210 mg/1.91 milliliters (110 mg/mL) in a glass vial (NDC 55513-100-01)
- Single-Dose Syringe Pre-filled: Carton contains one 210 mg/1.91 milliliter (110 mg/mL) pre-filled Syringe (NDC 55513-112-01)
Storage and Handling
Store in a cool, dry place between 36degF and 46degF (2degC to 8 degC). If needed, Tezepelumab-ekko may be kept at room temperature, ranging from 68degF and 77@F (20degC between 25 and 25degC) for up to 30 days. Don’t put it back in the refrigerator until Tezepelumab-ekko is at temperatures of room temperature. Once removed from the refrigerator Tezepelumab-ekko is to be utilized within 30 days or removed from the refrigerator.
Keep Tezepelumab-ekko in the original packaging to keep it safe from sunlight until the time of use.
Avoid freezing. Don’t shake. Avoid exposure to heat.
Label
More details
Always consult your doctor to make sure the information presented on this page is applicable to your particular situation.